Prospective Identification of Tumorigenic Prostate Cancer Stem Cells

Cancer Research - Tập 65 Số 23 - Trang 10946-10951 - 2005
Anne T. Collins1, Paul A. Berry1, Catherine Hyde1, Michael J. Stower2, Norman J. Maitland1
11Yorkshire Cancer Research Unit, Department of Biology, University of York and
22Department of Urology, York Hospital, National Health Service Trust, York, United Kingdom

Tóm tắt

Abstract Existing therapies for prostate cancer eradicates the bulk of cells within a tumor. However, most patients go on to develop androgen-independent disease that remains incurable by current treatment strategies. There is now increasing evidence in some malignancies that the tumor cells are organized as a hierarchy originating from rare stem cells that are responsible for maintaining the tumor. We report here the identification and characterization of a cancer stem cell population from human prostate tumors, which possess a significant capacity for self-renewal. These cells are also able to regenerate the phenotypically mixed populations of nonclonogenic cells, which express differentiated cell products, such as androgen receptor and prostatic acid phosphatase. The cancer stem cells have a CD44+/α2β1hi/CD133+ phenotype, and we have exploited these markers to isolate cells from a series of prostate tumors with differing Gleason grade and metastatic states. Approximately 0.1% of cells in any tumor expressed this phenotype, and there was no correlation between the number of CD44+/α2β1hi/CD133+ cells and tumor grade. The identification of a prostate cancer stem cell provides a powerful tool to investigate the tumorigenic process and to develop therapies targeted to the stem cell.

Từ khóa


Tài liệu tham khảo

Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259–65.

Nowell PC. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203–7.

Wodinsky I, Swiniarski J, Kensler CJ. Spleen colony studies of leukemia L1210. Differential sensitivities of normal hematopoietic and resistant L1210 colony-forming cells to 6-mercaptopurine (NSC-755). Cancer Chemother Rep 1967; 51: 415–21.

Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461–3.

Bonnet D, Dick JE. Human acute leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–7.

Al-Hajj M, Wicha S, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective isolation of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983–8.

Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821–8.

Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature 2004; 432: 396–401.

Bender Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823–35.

Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. J Cell Sci 2001; 114: 3865–72.

Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539–45.

Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239–45.

Collins AT, Zhiming B, Gilmore K, Neal DE. Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor. J Endocrinol 1994; 143: 269–77.

Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998; 58: 23–8.

van Leenders GJIH, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 2001; 21: 35–42.

Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002; 1: 113–21.

Dontu G, Wicha MS. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 2005; 10: 75–86.

Karan D, Schmied BM, Dave B, Wittel UA, Lin M-F, Batra SK. Decreased androgen responsive growth of prostate cancer is associated with increased genetic alterations. Clin Cancer Res 2001; 7: 3472–80.

Velasco A, Hewitt SM, Albert PS, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002; 94: 690–9.

Nupponen N, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone refractory recurrent prostate carcinomas. Am J Human Pathol 1998; 153: 141–8.

Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769–75.

Van Leenders G, van Balken B, Aalders T, Hulsbergen-ven de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implication for prostate cancer invasion. Prostate 2002; 51: 98–107.

Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005; 102: 6942–7.

Thông tin
Thông tin xuất bản

Cancer Research

Tập 65 Số 23

10946-10951

Thông tin tác giả